Spectris AD™ meaningfully reduced functional and cognitive decline in Alzheimer’s Disease over 6 months compared to sham treatment and was associated with 60-84% time savings. OVERTURE I Phase 2 MRI ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a leader in technology-based therapeutic interventions for neurodegenerative diseases, today announced that it will present four scientific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback